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Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined
with tumour-specific genetic alterations, hypoxia is a dominant factor in the angiogenic phenotype. Cellular adaptation to hypoxia is
an important requirement of tumour progression independent of angiogenesis. The adaptive changes, insofar as they alter hypoxia-
induced apoptosis, are likely to determine responsiveness to antiangiogenic strategies. To investigate this adaptation of tumour cells
to hypoxia, we recreated in vitro the in vivo situation of chronic intermittent exposure to low-oxygen levels. The colon carcinoma cell
lines HT29 and HCT116 were subjected to 40 episodes of sublethal hypoxia (4h) three times a week. The resulting two hypoxia-
conditioned cell lines have been maintained in culture for more than 2 years. In both cell lines changes in doubling times occurred: in
HT29 an increase, and in HCT116 a decrease. Cell survival in response to hypoxia and to DNA damage differed strikingly in the two
cell lines. The HT29 hypoxia-conditioned cells were more resistant than the parental line to a 24h hypoxic challenge, while those
from HCT116 surprisingly were more sensitive. Sensitivity to cisplatin in vitro was also significantly different for the hypoxia-
conditioned compared with the parental lines, suggesting a change in pathways leading to apoptosis following DNA damage signaling.
The growth of both conditioned cell lines in vivo as xenografts in immunodeficient (SCID) mice was more rapid than their parental
lines, and was accompanied in each by evidence of enhanced vascular proliferation as a consequence of the hypoxia-conditioning.
Thus the changes in apoptotic susceptibility were independent of altered angiogenesis. The derivation of these lines provides a model
for events within hypoxic regions of colon cancers, and for the acquisition of resistance and sensitivity characteristics that may have
therapeutic implications for the use of antiangiogenesis drugs.
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Hypoxia within solid tumours has been shown to be a determinant
of response to radiation and chemotherapy (Vaupel et al, 1989). A
consequence of the disordered vasculature that characterizes
growing tumours, hypoxia may occur locally as a consequence of
distance from capillary nutrient supply or regionally by virtue of
elevated tumour hydrostatic pressure or arteriolar vasoinstability
impeding blood flow. Most solid tumours, even those 1–3mm in
diameter, exhibit hypoxic fractions that may range from 10 to 30%
(Moulder and Rockwell, 1984). In tumours amenable to quantita-
tion of hypoxia using an O2 electrode, the proportion of hypoxic
cells is an important determinant of outcome (Bush et al, 1978;
Brizel et al, 1997). Hypoxia also selects for more aggressive and
metastatic cancer phenotypes that are associated with poor
prognosis (Hockel et al, 1996).
A major driver of the biology of hypoxic tumours is the
transcription factor HIF-1a (Carmeliet et al, 1998), which is
responsible not alone for altered gene expression, but also may
contribute to cancer progression and the development of a
phenotype more refractory to therapy (Harris, 2001). HIF-1a
increases angiogenesis through its regulation of VEGF expression
(Forsythe et al, 1996), an effect that may be hypoxia-independent
in some tumours (Semenza, 2003).
Cells rendered acutely hypoxic in vivo and in vitro show resistance
to alkylating agents and platinum compounds (Kennedy et al,1 9 8 0 ;
Tannock and Guttman, 1981; Teicher et al, 1990; Brown and Koong,
1991; Sakata et al, 1991). The basis for this resistance has been
partially elucidated in recent years. In addition to HIF-1a,h y p o x i c
cells have been shown to express higher levels of enzymes that are
responsible for detoxication of cytotoxic drugs (O’Dwyer et al, 1994).
Exposure of colon cancer cells to hypoxia results in altered
expression of genes regulated by the AP-1 and NF-kB transcription
factor families, with recognized functional consequences (Yao et al,
1994; Yao and O’Dwyer, 1995), and not unexpectedly, microarray
analyses reveal the induction of multiple transcripts from various
functional groups (Koong et al, 2000). The relationship of gene
expression changes to resistance to apoptosis induced by DNA-
damaging agents is relevant to the clinical treatment of cancer.
Several groups have shown that hypoxia itself may induce apoptosis
(Yao et al, 1995; Shimizu et al, 1996; Amellem et al, 1997; Kim et al,
1997), and these observations form the basis of therapeutic efforts Revised 19 September 2005; accepted 22 September 2005
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sdirected to the tumour vasculature (Chaplin and Hill, 2002).
Therefore, we wished to understand the basis for resistance to
apoptosis in hypoxic tumour cells.
Numerous examples exist in cancer therapeutics of the
induction of drug resistance in cell lines by repeated exposure to
the agent to which resistance is being induced (Kartner et al, 1983;
Buller et al, 1987; Godwin et al, 1992). Such studies have served to
identify resistance mechanisms that subsequently have been
targets for the development of reversal strategies. We have adopted
a similar approach to the identification of genes mediating hypoxic
cell resistance by deriving cell lines through their repeated
exposure to short periods of hypoxia (4h), a duration shorter
than that required to induce apoptosis. The colon adenocarcinoma
cell lines HT29 (which is characterized by mutated p53), and
HCT116 (which is characterized by wild-type p53 and micro-
satellite instability) were subjected to thrice-weekly treatments,
and cell lines isolated after 40 treatments. In this manuscript, we
present the divergent responses of these cell lines to hypoxia and
to DNA-damaging agents. The conditioned cell lines were
concordant, however, in their upregulation of angiogenesis, which
correlated more closely with their growth characteristics in vivo.
These findings support a role for these cell lines in exploring the
basis for hypoxic cell sensitivity and resistance.
MATERIALS AND METHODS
Establishment of hypoxia-conditioned cell lines
HT29 and HCT116 human colon cancer cells were seeded in glass
milk bottles and cultured in MEM medium supplemented with
10% FBS. The cells were exposed to hypoxia (0.1% O2) for 4h and
were then incubated in a standard culture environment (5%CO2,
95% air), at 371C for 48–72h. Cells were treated thrice weekly. The
hypoxia-conditioned cell lines were derived by repeated exposure to
hypoxia in this manner of both HT29 and HCT116, resulting in the
generation of cell lines from HP10 to HP40 (from HT29) and HCP10
to HCP40 (from HCT116) respectively, following 40 exposures to
hypoxia. A similar procedure was followed for the derivation of
hypoxia-conditioned cells from a p53
 /  derivative of HCT116
(kindly provided by B Vogelstein, Johns Hopkins University).
Cell growth parameters and cell cycle analysis
The cell doubling times were obtained by direct measurement of
cell numbers. Cells (1 10
4/dish) were plated in triplicate and
incubated at 371Ci n5 %C O 2, 95% air. The cells were harvested at
24, 48, 72 and 96h after plating. Doubling times were calculated
using the formula: N/N0¼e
kt where N is the cell number for a cell
line at a particular time (t) and N0 is the corresponding cell
number at time 0. The constant k was calculated for each cell line
between 24 and 96h, the period of time in which the cell growth
rate was linear. The doubling time was then determined using the
above formula with N/N0¼2. For cell cycle analysis, cells (3 10
6)
were harvested by trypsinization, washed with cold PBS, and
resuspended in 0.5ml PBS, to which was added 5ml cold 70%
ethanol, followed by storage at  201C until analysis. Before
being analysed, cells were washed with PBS, resuspended in 455ml
PBS, followed by addition of 25ml propidium iodide staining
solution (1mgml
 1) and 20ml RNase (1mgml
 1). The suspension
was then incubated at least 30min in the dark, and analysed by
flow cytometry.
Identification of morphological differences produced by
hypoxic conditioning cell lines
The hypoxia-conditioned cell lines HP40, HCP40, and control
HT29 and HCT116 cells were evaluated for apparent morpholo-
gical differences by light microscopy.
Cytogenetic analysis
Cytogenetic analysis was performed on HT29 and HCT116, and the
hypoxia-conditioned cell lines HP40 and HCP40. Metaphase cells
were arrested by exposing cell overnight to colcemid
(0.03mgml
 1). Chromosome spreads were prepared and G-banded
according to standard procedures. Chromosome counts were
obtained from at least 20 metaphase cells, and karyotypes were
prepared from 5 to 10 of these cells, whenever possible.
Chromosome identification and karyotype designations were in
accordance with accepted guidelines for cancer cytogenetics
(Mitelman, 1995).
In vitro cytotoxicity assay
Cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Mosmann, 1983).
For the drug cytotoxicity assay, cells were plated in 150mlo f
medium in each well of 96-well plates. Following overnight
incubation, cells were exposed to various concentrations of cisplatin
or oxaliplatin. Following 72h incubation, 40ml of 5mgml
 1 MTT
was added per well. After 2h at 371C, the cells were lysed by adding
100ml of 20% (wv
 1) SDS, and 50% (vv
 1) N,N-dimethylformamide
(pH 4.7) and incubated 3h at 371C. The absorbance at 570nm was
determined using a microplate reader (Elx800, BioTek Instruments
Inc.). The reported values are the result of duplicate determinations.
For cytotoxicity under hypoxia, cells were plated at a density of
3000cellswell
 1 in 96-well plates. The plated cells were incubated
overnight at 371C, in 5% CO2 and 95% air. The cells were exposed to
cisplatin or oxaliplatin, or to no drug for the hypoxic survival
experiments, and placed in the anaerobic chamber (Forma Scientific
Inc., Waltham, MA, USA) which was gassed using oxygen-poor (less
than 1 part per 10 billion) 95% N2 and 5% CO2.A f t e ra2 4 h
incubation in the anaerobic chamber, cells were transferred to the
incubator at 371C, 5% CO2 and 95% air for additional 48h, after
which the MTT assay was performed as described above. The data
shown in MTT assay are means7s.d. of two independent
experiments carried out in triplicate. The statistical significance of
the difference between control and hypoxia-treated with or without
drug group was assessed by the two-sample Student’s t test between
two paired samples.
TUNEL assay
Quantitation of apoptotic cells under hypoxic and oxic conditions
was obtained using the TUNEL assay, which was performed
according to the protocol of the Cell Death Detection Kit (Roche,
Piscataway, NJ, USA). Cells were plated in glass petri dishes at a
density of 1 10
6/dish. Following overnight incubation under oxic
conditions, the cells were incubated in the anaerobic chamber for
24h. They were harvested, washed in PBS/1% BSA at 41C, and
fixed using a freshly prepared paraformaldehyde solution (4% in
PBS, pH 7.4). After washing with PBS, cells were then treated with
permeabilisation solution (0.1% Triton X-100 in 1% sodium
citrate) for 2min on ice. The cells were washed with twice with
PBS, labeled with the TUNEL reaction mixture, and incubated for
60min at 371C in a humidified atmosphere in the dark. The
reaction was stopped by adding 500ml of PBS. The apoptotic cells
were quantitated by flow cytometry.
Cell invasion assay
The capacity of the cell lines to exhibit invasive characteristics was
determined using a Matrigel Invasion Chamber following the
manufacturer’s procedure (BD Biosciences, Bedford, MA, USA).
Briefly, 1.25 10
5cellsml
 1 were seeded in each chamber of a six-
well dish. The chambers were prehydrated for 2h in an incubator
at 371Ci n5 %C O 2 and 95% air. After adding the cells, the Matrigel
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sinvasion chambers were incubated for a further 22h at 371Ci n5 %
CO2/95% air, after which cells were fixed and stained by Coomassie
blue solution for 30min, and washed three times in PBS. After air-
drying, the cells were counted. Control chambers without Matrigel
were used to estimate migration rates. The invasion index
was calculated as the ratio of cell numbers invading/migrating,
and the hypoxia-conditioned cells were compared to their parental
cell lines.
Growth of the Conditioned cell lines in vivo
Adult (8–10 weeks of age) female C.B.17 SCID mice were
purchased from Charles River Laboratories (Wilmington, MA,
USA) for in vivo studies. The colon carcinoma cell lines HT29 and
HCT116 and their respective hypoxia-conditioned cell lines HP40
and HCP40 were grown as a monolayer, and then trypsinised,
washed, and resuspended in PBS. tumours were generated by
subcutaneous injection of 1 10
7 cells in 100ml PBS into the left
flank of SCID mice. In one experiment, the hypoxia resistant cell
lines HP40 and HCP40 were cultured in hypoxic conditions for 6h
1 day prior to implantation, while in the second, the cells were
used without further treatment. Subsequent tumour size was
measured every 3 days using Vernier calipers, and the tumour
volume calculated using the formula 1/2 (length
2 width). For
tumour weight measurement and histochemical staining, tumour-
bearing mice were killed on day 33, and tumours removed and
snap frozen. Each experimental group consisted of six to eight
SCID mice. The data shown are means7s.d. of mice in each group.
All the animal experiments were performed in compliance with the
NIH Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee.
Northern blotting
Total RNA was isolated using the Trizol reagent (Gibco BRL,
Grand Island, NY, USA). Briefly, 10
7 cells were lysed in 3ml Trizol
reagent and incubated for 5min at room temperature. After adding
0.6ml of chloroform, the tube was vortexed and incubated at room
temperature for 5min. The sample was centrifuged at 12000g for
15min at 41C. The aqueous phase was mixed with 1.5ml of
isopropyl alcohol to precipitate the RNA, and again centrifuged at
12000g for 15min at 41C. The RNA pellet was washed once with
70% ethanol, and dissolved in DEPC-treated water. RNA was
separated by electrophoresis in a 1% agarose denaturing gel. The
RNA was transferred to nylon membranes, and hybridized to a
550bp cDNA VEGF probe, or a 780bp cDNA HIF-1a probe. A
b-actin probe was used a loading control. Membranes were washed
for 1h in 2  SSC containing 0.5% SDS and at 601C, followed by
1h in 0.1  SSC containing 0.5% SDS. The filters were exposed to
X-ray film at 701C for 1–5 days.
Immunohistochemistry
The frozen-sections fixed in cold acetone. The slides were treated
for antigen retrieval by boiling for 10min with 0.01 M citrate buffer
pH 6.0. After antigen retrieval, slides were blocked with 1% BSA/
Tris-buffered saline for 15min. After a PBS wash, slides were
incubated with rat anti-mouse CD31 (PECAM-1) monoclonal
antibody (1:200 dilution: BD Biosciences Pharmingen, San Diego,
CA, USA) at 41C overnight, followed by incubation with
biotinylated anti-rat antibody (Dako Corporation, Carpinteria,
CA, USA) and horseradish peroxidase-conjugated streptavidin
(Dako). Signals were visualized with diaminobenzidine as the
substrate. The tissues were counterstained with hematoxylin.
Normal rat antibody was used as a negative control. The
quantitation of blood vessels in cross-sections of the tumours
was based on the procedure described previously (Stephan
et al, 2004).
Statistics
Comparisons of quantitative measures between the cell lines were
performed using t-tests, and Pp0.05 accepted as significant.
RESULTS
Growth characteristics and morphology
Cell lines were derived by repeated exposure of the colon cancer
cell line HT29 (a p53 mutated line, with intact mismatch repair,
and a chromosomal instability [CIN
þ] phenotype) and HCT116 (a
p53 wild-type line, with a defect in DNA mismatch repair but no
chromosomal instability [CIN
 ]) to 4h periods of hypoxia thrice
weekly, resulting in the generation of cell lines HP40 and HCP40,
respectively, each reflecting 40 exposures to hypoxia. The
conditioned cell line HP40 displayed an increase in doubling time
from 25.9h in the parental line to 33.6h (Po0.05) (Table 1). The
conditioned cell line HCP40, by contrast, assumed a more
proliferative program, and displayed a gradual decrease in
doubling times from 28.5h in the parental line to 20.5h in
HCP40, which was also significant (Po0.05). These changes were
maintained for over 2 years in continuous culture, indicating
their long-term effects. Thus repeated exposure of the cells to
hypoxia led to stable changes in the proliferative characteristics
of these colon cancer cells, in a manner that differed between the
two cell lines.
The change in doubling time was not reflected in a marked
change in cell cycle distribution under oxic conditions when
measured 24h after plating (Table 1). When exposed to hypoxia,
however, the conditioned cells responded differently from parental
cells. When HT29 cells are exposed to hypoxia, there was an
apparent delay in progression into G2/M with a small increase in
the proportion of cells in S (14–18%). This was not observed when
HP40 cells were exposed to hypoxia, and cell cycle distribution was
unchanged. On the other hand, a modest G1 arrest (51–62%)
observed in the parental line (HCT116) did not occur in the
conditioned cells (HCP40).
Cytogenetics
The cytogenetic analysis of HCP40 and HP40 was conducted on a
minimum of 20 metaphases per cell line. The karyotypes of the
hypoxia-conditioned cell lines are identical to that of the parental
Table 1 Growth characteristics of HT29 and HCT116-derived cell lines
before and after repeated 4h exposures to hypoxia. Doubling times and
cell cycle distribution in oxic conditions were measured under standard
culture conditions
Cell line HT29 HP40 HCT 116 HCP40
Doubling time (h) 25.972.3 33.871.9* 28.5 71.7 20.571.1*
Cell cycle distribution
Oxic conditions
G0/G1 (%) 72.5 71.5 50.6 54.8
G2/M (%) 8.5 9.5 23.5 20.2
S (%) 13.9 16.5 22.7 20.5
Hypoxic conditions
G0/G1 (%) 59.3 74.1 62.4 47.5
G2/M (%) 10.7 11.5 10.2 9.4
S (%) 18.2 12.3 11.9 9.2
Cell cycle analysis under hypoxic conditions was conducted after a 24h exposure to
hypoxia, and included adherent and floating cells. * denote a statistically significant
difference between parental cell line and its hypoxia-conditioned derivative with
P-value o0.05).
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scell line HCT116 and HT29 (data not shown). Thus gross
alterations of chromosomal structure do not underlie the observed
phenotypes.
Apoptotic response of conditioned cells to hypoxia
We and others have previously shown that hypoxia is a relatively
strong inducer of apoptosis in cell lines in vitro,a n dh a v e
investigated the pathways involved (Pandey et al, 1999; Vasilevskaya
and O’Dwyer, 1999; Garay et al, 2000). We studied the survival
of the conditioned cells following varying durations of hypoxia
and assessed outcome using the MTT assay (Figure 1). As with
our previous studies of HT29 cells, an 8h exposure to hypoxia
had minimal effects on survival (data not shown). However,
extending the hypoxic period to 16 or 24h markedly compromised
the survival of the cells. The HT29 series showed progressive
acquired resistance to hypoxia from HP10 (the cell line derived
after 10 exposures to hypoxia) to HP40, which demonstrated
greater survival following a 24h hypoxia exposure than HT29:
85.772.9 vs 73.871.7% (Po0.05). The opposite effect was
observed with the HCT116-derived series: progressively greater
susceptibility to hypoxia was observed to the point that the
survival of HCP40 after 24h of hypoxia (34.672.3%) was
substantially less than that of the parental line (70.874.5%,
Po0.05). Since the colorimetric assay may not distinguish between
cell death and delayed growth, we performed a TUNEL assay to
assess the proportion of cells in which apoptosis was induced. In
this assay also (Table 2), the HT29-derived cells were more
resistant: in HT29, 12.8% were apoptotic vs 2.1% in HP40
(Po0.05). By contrast, the HCP40 conditioned cells were
substantially more susceptible: after an 8h hypoxic exposure,
15.5% of the parental HCT116 cells were apoptotic vs 33.9% for
HCP40 (Po0.05). Thus the HT29 derived cells had become more
resistant to hypoxia, as expected, whereas the HCT116 series
became more sensitive, despite a more aggressive phenotype in cell
growth characteristics.
We hypothesized that the difference in p53 competence between
the cell lines may account for the opposing directions of sensitivity
to hypoxia upon repeated hypoxic stress. A similar procedure was
followed to derive hypoxia-conditioned cells from HCT116/p53
 / ,
a p53-knockout cell line that has been well characterized in
previous studies (Bunz et al, 1999). As anticipated, loss of p53
indeed influenced the direction of change in hypoxia sensitivity:
the p53
 /  cells developed along the same lines as HT29, and
became more resistant to apoptosis (Table 2).
Sensitivity of conditioned cells to DNA-damaging agents
To determine if the observed changes were specific to a hypoxic
mechanism of cell death, or reflected a more general effect on
apoptotic responses, we investigated the effects of a DNA-
damaging agent. Cells were treated with varying concentrations
of cisplatin under oxic and hypoxic conditions (Figure 2). Both
parental cell lines are moderately sensitive to cisplatin when fully
oxygenated. Hypoxia confers slight resistance to cisplatin in
HT29 but not in HCT116 cells. Under oxic conditions, HT29-
derived conditioned cells are slightly more resistant, and HCT116-
derived cells more sensitive than their parental equivalents. A
marked alteration in cisplatin sensitivity is observed in the
conditioned cells under hypoxia, however. The HCP40 cells are
7.0-fold more sensitive to cisplatin (Po0.05), while HP40 are over
2.2-fold more resistant (Po0.05). The findings with oxaliplatin are
very similar: HP40 is more resistant than HT29, while HCP40 is
more sensitive than HCT116 (data not shown). Therefore, changes
in sensitivity to platinum-induced and hypoxia-induced apoptosis
vary among the cells in a concordant manner, implying that the
change in apoptotic regulation in response to hypoxia condition-
ing occurs at a level downstream of the decision to commit to
apoptosis.
Invasive and migratory ability of the hypoxia-conditioned
cells
The role of tumour cell invasion in determining the metastatic
capacity of cancers has long been recognized (Liotta et al, 1982).
Interactions with the cell matrix have been demonstrated to
determine the behavior of in vivo models of human cancer, and
efforts to target these interactions clinically have been made
(Melchiori et al, 1992; Coussens et al, 2002; Egeblad and Werb,
2002). Recent data support a role for inhibition of specific matrix
metalloproteinases (MMP’s) in preventing invasion/metastasis
(Holmbeck et al, 2003), and the potential to target relevant MMP’s
selectively may provide therapeutic targets. The invasive potential
of hypoxia-conditioned cell lines was determined in an in vitro
invasion chamber over a 22h period (Table 3). The ability of the
cells to invade Matrigel-coated filters is presented as the invasion
index, the ratio of invasion through Matrigel divided by a control
for cell motility. The results show that the HCP40 cells have a
significantly higher invasion index compared to the parental
HCT116 cells (7.1-fold increase, Po0.05), while HT29 and HP40
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Figure 1 Survival of conditioned cells following various periods of
hypoxia, as measured by the MTT assay. Cells were exposed to hypoxia for
4h three times weekly, for up to 40 exposures (corresponding to HP10 to
HP40 and HCP10 to HCP40), and cells harvested and stored after every
10 hypoxic treatments. For analysis of survival in hypoxia, cells were plated
in 96-well plates, exposed to profound hypoxia for the durations indicated,
and cultured under oxic conditions for an additional 72h.
Table 2 Apoptosis (%) in hypoxia-conditioned cell lines
Cell line HCT116 HCP40 HT29 HP40 HCT116( / ) HCP40( / )
Oxic 3.270.3 4.570.2 4.170.3 2.570.1 3.370.2 3.070.3
Hypoxia 15.571.1 33.972.7* 12.870.8 2.170.2* 7.570.7 3.970.5*
HT29 and HCT116 and their hypoxia-conditioned derivatives, HP40 and HCP40, were exposed to 24h of hypoxia as described. In addition, apoptosis was measured in a
matched pair of HCT116/p53
 /  cells conditioned and treated similarly. *Denote a statistically significant difference between parental cell line and its hypoxia-conditioned
derivative with P-value o0.05.
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scells show no significant differences. These findings are con-
cordant with observations on surface adhesion (greater invasive
capacity and less adherence to surfaces).
Growth of the conditioned cell lines in vivo
We transferred the conditioned cell lines to an in vivo model by
subcutaneous injection of SCID mice with 10
7 cells in the flank,
followed by tumour measurement twice weekly. The take rate was
100%. The growth characteristics of these tumours (six to eight
animals/group) are shown in Figure 3. HCP40 grown in vivo
recapitulates its in vitro growth characteristics growing more
rapidly than the parental HCT116. The growth of HP40, however,
is also more rapid than that of the parental HT29, despite its longer
doubling time in vitro. Most interestingly, HCP40 starts its growth
earliest of all the cell lines, suggesting that the conditioned line has
acquired an ability to establish an optimal microenvironment, or
conversely to evade environmental constraints upon such growth.
Conditioned cell lines display a more angiogenic profile
in vivo
We hypothesized, therefore, that the vascularization of the
tumours in vivo may have been affected by the in vitro hypoxia
conditioning. We analysed vascular endothelial growth factor
(VEGF) expression in the tumour cells by northern analysis
(Figure 4A). Induction of VEGF expression by hypoxia is observed
in all cell lines, but both of the conditioned cell lines display
upregulation of VEGF expression even under oxic conditions.
A possible contribution of HIF-1a to this phenotype was explored
in a preliminary fashion: in all cell lines HIF-1a is induced by
hypoxia, but unlike VEGF, the baseline RNA expression of this
gene is not elevated in oxic conditioned cells (Figure 4A). Western
analysis showed similar profiles of HIF-1a protein expression (data
not shown). This finding suggests that baseline elevation of VEGF
transcription in these cells may be through VEGF-independent
mechanisms. Sections of tumours grown in vivo were stained for
microvessels using CD31 antibody (Figure 4B). The microvessel
density was increased in tumours derived from both the
conditioned cell lines derived from HT29 (1371.8 vs 2171.9
(mean7s.d.)) and from HCT116 (871.5 vs 1772.1), and the
increase is evident from the immunohistochemical image. The
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Figure 2 Sensitivity of hypoxia-conditioned cell lines to cisplatin as
measured by the MTT assay. Cells were plated in 96-well plates, and after
18–24h to allow adherence, a range of concentrations of cisplatin was
added. For hypoxic incubation, the plates were immediately placed in the
anaerobic chamber, left for 24h at 371C, and returned to an oxic
environment for an additional 48h. The MTT assay was performed at 72h
after initial exposure to the drugs in all cells. The one asterisk denotes the
statistically significant difference between hypoxia-conditioned cell lines and
its parental cell line with P-value o0.05.
Table 3 Invasive and migratory ability of hypoxia-conditioned cells HP40
and HCP40 compared to their parental cells
Cell line
HT29 (control
cells) HP40 (test cells)
# cells invasion MIC (mean
of triplicate)
4.3 5.3
% Invasion 4.6 6.4
Invasion Index 6.4/4.6¼1.4
Cell line HCT116 (control
cells)
HCP40 (test cells)
# cells invasion MIC (mean
of triplicate)
8.0 56.0
% Invasion 3.9 28.0
Invasion Index 28.0/3.9¼7.1*
*denotes the statistically significant difference in invasion index between HP40 and
HCP40.
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Figure 3 Tumour growth curve of HT29, HP40 (A), and HCT116,
HCP40 (B) in SCID mice. tumours were generated by subcutaneous
injection of 10
7 cells in the left flank, and bidimensional measurements
made every three days. The curves shown are the combined results of two
separate experiments, the results of which were comparable.
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sobservation of increased vascularity in both models is consistent
with their in vivo growth characteristics, in that both conditioned
cell lines grow more rapidly than their parental lines (Figure 3).
The increased susceptibility to apoptosis on the part of the
HCT116-derived cell line does not therefore confer a growth
disadvantage under nonstressed conditions (i.e. in the absence of a
proapoptotic stimulus, such as would be provided by chemo-
therapy). This finding is consistent with the low levels of activity
observed with single agent antiangiogenic treatment in most solid
tumours.
DISCUSSION
Angiogenesis in tumours represents the interaction of cancer cells,
stromal cells and the endothelium of local blood vessels. The
dysregulation of this interaction is reflected in the abnormal
structure of the tumour vasculature, which results ultimately in
areas of hypoxia. Hypoxic cells have altered responses to radiation
and to cytotoxic drugs, and hypoxia has long been known to be a
cause of resistance of cancer to treatment, be it with radiation or
cytotoxic drugs (Bush et al, 1978; Kennedy et al, 1980; Tannock
and Guttman, 1981; Vaupel et al, 1989; Teicher et al, 1990; Brown
and Koong, 1991; Sakata et al, 1991; Brizel et al, 1997). Hypoxic
cells also have the propensity to acquire genetic abnormalities that
confer a ‘more malignant’ phenotype. For example, gene
amplification was described to result from brief exposure of
Chinese hamster ovary cells to hypoxia (Rice et al, 1986). Hypoxia
can give rise to loss of p53 function in hypoxic transformed mouse
embryonic fibroblasts, as a consequence of the acquisition of
mutations (Graeber et al, 1996). More recently, some cell lines
exposed to hypoxia are reported to be less susceptible to apoptosis
(Dong and Wang, 2004; Zhang and Hill, 2004). Thus the hypoxic
environment provides a vehicle for the clonal evolution of tumours
to more advanced stages of carcinogenesis. The relationship
between these observations and the resistant phenotype may
usefully be explored using cell lines with acquired changes in
responses to hypoxia. We report the characterization of a series of
cell lines derived from two widely used colon carcinoma models,
HT29 and HCT116. HT29 bears a mutation in one allele of p53, but
based on p21 responses is functionally p53-deficient; HCT116 has
normal p53 function, but is defective in mismatch repair resulting
in the microsatellite instability phenotype (Rodrigues et al, 1990;
Bhattacharyya et al, 1994).
Previous studies of acquired cytotoxic drug resistance have
utilized cell lines with resistance acquired through repeated
exposure to escalating concentrations of the drug of interest. This
work has led to the isolation and characterization of numerous
genes related to resistance, including the multiple drug resistance
(mdr-1) gene and other members of the ATP-binding cassette
membrane transporters, and participants in thiol-mediated drug
detoxication (Ling et al, 1983; Hamilton et al, 1985; Wang and
Tew, 1985). The protein products of these genes are now targeted
by specific inhibitors in clinical trials. We have adopted a
similar approach to the isolation of genes mediating hypoxic cell
resistance. Colon cancer cells have been exposed repeatedly to
sublethal periods of hypoxia, and cell lines isolated and
characterized. We find that the resulting cell lines have acquired
marked changes from the parental line, and that the conditioned
cells are altered in their sensitivity both to hypoxia and to the
cytotoxic drugs cisplatin and oxaliplatin. The concordant associa-
tion of resistance and sensitivity to both of these stimuli is of some
interest in that it is consistent with well-established data showing
that hypoxic tumours are resistant to radiation also (Brown, 1999;
Harris, 2001). It suggests that these stimuli may activate common
response pathways to apoptosis, and further that the alteration in
apoptosis sensitivity in the conditioned cell lines is downstream of
the lesion that determines lethality, in the pathways mediating
cellular responses to the damage. Apoptosis susceptibility is
recognized to be critical to the effectiveness of anticancer therapy
(Johnson et al, 1997; Johnstone et al, 2002). HIF-1a is a target for
the development of drugs to reverse hypoxic resistance (Semenza,
2003): in this model it seems unlikely that HIF-1a is the major
cause of the observed changes in susceptibility based on its profile
of response to hypoxia, which does not differ as far as we can
determine, between the sensitive and resistant lines. These cells
may be a source therefore of novel targets to alter susceptibility to
apoptosis in response to hypoxia and other stimuli.
Most striking in these results is the divergence of the fates of the
cell lines derived by the same stimulus. Our initial purpose in
developing these lines was to derive a hypoxia-resistant series of
cell lines. The HT29-derived cell lines are indeed hypoxia-resistant,
and capable of surviving prolonged extreme hypoxia. Clearly
events that underlie this change are relevant to cells that fail to
respond to antiangiogenic therapy. Unlike Dong and Wang (Dong
and Wang, 2004), we did not find abnormalities in expression of
bcl-2 family members to explain the resistance to apoptosis (data
not shown). We were, however, able to show an effect of p53 in
determining the development of resistance. HCT116 cells in which
p53 was knocked out became resistant. Unexpectedly, the parental
HCT116-derived lines proved more sensitive to the apoptosis-
inducing effects of both hypoxia and cisplatin. Although the
conditioning period was only 4h, selection of a more sensitive
population in the face of a toxic stimulus would be an unlikely
violation of natural selection in the absence of a factor conferring
a growth advantage. Presumably the accelerated growth rate
provides this advantage, and raises the question of the link
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Figure 4 (A) Northern blot of RNA from the cell lines indicated, under
oxic or hypoxic (16h) conditions, probed with human VEGF and HIF-1a
cDNAs. (B) Immunohistochemistry of formalin-fixed, paraffin-embedded
tumour sections following 7 days’ tumour growth of HT29, HP40, HCT116
and HCP40 implanted subcutaneously in scid mice. Sections of tumour
were incubated with rat anti-mouse CD31, and developed by an
immunoperoxidase technique.
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sbetween growth rate and susceptibility to apoptosis. Such a link
has been postulated through dysregulated E2F transcriptional
activity increasing the content of both initiator and effector
caspases (Nahle et al, 2002). A possible role for p53 is also
suggested by the findings with HCT116 p53 /  cells, and data
support a role for p53 in hypoxia-induced apoptosis (Leker et al,
2004). North et al (2005) have suggested that p53 may be involved
in the angiogenic switch in some tumours. Altered growth
characteristics in cell lines subjected to selection pressure has
frequently been reported, but the underlying cause has rarely been
identified, and generally the selected lines grow more slowly
(Louie et al, 1992; Gibelli et al, 1996; Hochachka et al, 2002).
We hypothesize that a mutational event is responsible for both
increased susceptibility to apoptosis and the altered doubling
time, consistent with the previous demonstration that the
hypoxic environment facilitates mutational events (Graeber et al,
1996) and plausible especially in a cell line deficient in DNA
mismatch repair. In this case, the development of a more
apoptosis-prone cell line seems to be an evolutionary event in an
environment to which tumour cells are commonly exposed in vivo.
The means by which such intratumoural evolution is accelerated is
under investigation.
Finally, this regimen of hypoxia conditioning in vitro altered the
angiogenesis activity of the resulting tumours grown in vivo.
Irrespective of susceptibility to apoptosis, both conditioned cell
lines demonstrated an increase in VEGF expression, and when
grown in vivo, enhanced angiogenesis, and this was associated with
more rapid growth in vivo of tumours derived from each. VEGF
expression is therefore dissociated from susceptibility to apopto-
sis. A contribution of VEGF to survival of cancer cells by
antagonizing semaphorin signaling has recently been demon-
strated to occur in lung and breast cancer cell lines (Castro-Rivera
et al, 2004). These observations imply that a growth advantage of
cells in a hypoxic environment is achieved in part by upregulation
of proangiogenic factors, which in this model would appear to
outweigh the importance of apoptosis susceptibility. These colon
cancer cells provide therefore a model that may be relevant to the
investigation of colon cancer therapy, especially in light of the
recent demonstration of the effectiveness of antiangiogenic
approaches in this disease.
ACKNOWLEDGEMENTS
This work is supported in part by CA49820 from NCI/NIH/DHHS.
REFERENCES
Amellem O, Stokke T, Sandvik JA, Smedshammer L, Pettersen EO (1997)
Hypoxia-induced apoptosis in human cells with normal p53 status and
function, without any alteration in the nuclear protein level. Exp Cell Res
232: 361–370
Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M (1994)
Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl
Acad Sci USA 91: 6319–6323
Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor
hypoxia adversely effects the prognosis of carcinoma of the head and
neck. Int J Radiat Oncol Biol Phys 38: 285–289
Brown JM, Koong A (1991) Therapeutic advantage of hypoxic cells in
tumors: a theoretical study. J Natl Cancer Inst 83: 178–185
Brown JM (1999) The hypoxic cell: a target for selective cancer therapy –
eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:
5863–5870
Buller AL, Clapper ML, Tew KD (1987) Glutathione S-transferases in
nitrogen mustard-resistant and – sensitive cell lines. Mol Pharmacol 31:
575–578
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams
J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in
human cancer cells alters the responses to therapeutic agents. J Clin
Invest 104: 263–269
Bush RS, Jenkin RDT, Allt WEC (1978) Definitive evidence for hypoxic cells
influencing cure in cancer therapy. Br J Cancer 37(Supp III): 302–306
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin
M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P,
Moons L, Jain RK, Collen D, Keshert E (1998) Role of HIF-1alpha in
hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature 394: 485–490
Castro-Rivera E, Ran S, Thorpe P, Minna JD (2004) Semaphorin 3B
(SEMA3B) induces apoptosis in lung and breast cancer, whereas
VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 101: 11432–
11437
Chaplin DJ, Hill SA (2002) Selective induction of tumor ischemia:
development of vascular targeting agents for cancer therapy. Curr Opin
Investig Drugs 3: 1381–1384
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science 295: 2387–2392
Dong Z, Wang J (2004) Hypoxia selection of death-resistant cells: a role for
Bcl-XL. J Biol Chem 279: 9215–9221
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases
in cancer progression. Nat Rev Cancer 2: 161–174
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL
(1996) Activation of vascular endothelial growth factor gene transcrip-
tion by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613
Garay M, Gaarde W, Monia BP, Nero P, Cioffi CL (2000) Inhibition of
hypoxia/reoxygenation-induced apoptosis by an antisense of oligonu-
cleotide targeted to JNK1 in human kidney cells. Biochem Pharmacol 59:
1033–1043
Gibelli N, Zibera C, Asti A, Kaestri L, Bacchella L, Pedrazzoli P, Calligaro A,
Robustelli della Cuna G (1996) CG5/Dx human breast cancer cell lines:
characterization of a new doxorubicin-resistant variant. Anticancer Res
16: 1675–1681
Godwin A, Meister A, O’Dwyer PJ, Huang C, Hamilton T, Anderson M
(1992) High resistance to cisplatin in human ovarian cancer cell lines is
associated with marked increase of glutathione synthesis. Proc Natl Acad
Sci USA 89: 3070–3074
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW,
Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished
apoptotic potential in solid tumours. Nature 379: 88–91
Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T,
Grotzinger KR, McKoy WM, Young RC, Ozols RF (1985) Augmentation
of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant
and -sensitive human ovarian carcinoma cell lines by buthionine
sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:
2583–2586
Harris AL (2001) Hypoxia – a key regulatory factor in tumor growth. Nat
Rev Cancer 2: 38–46
Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P (2002)
Going malignant: the hypoxia-cancer connection in the prostate.
Bioessays 24: 749 –757
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996)
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res 56: 4509–4515
Holmbeck K, Bianco P, Birkedal-Hansen H (2003) MT1-mmp: a collagenase
essential for tumor cell invasive growth. Cancer Cell 4: 83–84
Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased
platinum-DNA damage tolerance is associated with cisplatin resistance
and cross-resistance to various chemotherapeutic agents in unrelated
human ovarian cancer cell lines. Cancer Res 57: 850–856
Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between
cancer genetics and chemotherapy. Cell 108: 153–164
Kartner N, Shales M, Riordan JR, Ling V (1983) Daunorubicin-resistant
Chinese hamster ovary cells expressing multidrug resistance and a cell-
surface P-glycoprotein. Cancer Res 43: 4413–4419
Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC (1980) The hypoxic
tumor cell: a target for selective cancer chemotherapy. Biochem
Pharmacol 29: 1–8
Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo
JA, Peehl DM, Giaccia AJ (1997) Selection of human cervical epithelial
Hypoxia conditioned cell lines and angiogenesis
K Yao et al
1362
British Journal of Cancer (2005) 93(12), 1356–1363 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scells that possess reduced apoptotic potential to low-oxygen conditions.
Cancer Res 57: 4200–4204
Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans
S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ (2000) Candidate genes for the
hypoxic tumor phenotype. Cancer Res 60: 883–887
Leker RR, Aharonowiz M, Greig NH, Ovadia H (2004) The role of p53-
induced apoptosis in cerebral ischemia: effects of the p53 inhibitor
pifithrin alpha. Exp Neurol 187: 478–486
Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR (1983) Multidrug-
resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep
67: 869–874
Liotta LA, Thorgeirsson UP, Garbisa S (1982) Role of collagenases in tumor
cell invasion. Cancer Metast Rev 1: 277–288
Louie KG, Hamilton TC, Shoemaker RH, Young RC, Ozols RF (1992)
Evaluation of in vitro drug screening leads using experimental models of
human ovarian cancer. Invest New Drugs 10: 73–78
Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG (1992) Inhibition of
tumor cell invasion by a highly-conserved peptide sequence from the
matrix metalloproteinase enzyme prosegment. Cancer Res 52: 2353–2356
Mitelman F (ed). (1995) An international System for Human Cytogenetic
Normenclature. S. Karger, Basel, ISCN
Mosmann T (1983) Rapid colorimetric assay for cellular growth and
survival: application to proliferations and cytotoxicity assays. J Immuno
Methods 65: 55–63
Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors:
experimental techniques, methods of analysis, and a survey of existing
data. Int J Radiat Oncol Biol Phys 10: 695–712
Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M,
Zhang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW (2002) Direct coupling of
the cell cycle and cell death machinery by E2F. Nat Cell Biol 4: 859–864
North S, Moenner M, Bikfalvi A (2005) Recent developments in the
regulation of the angiogenic switch by cellular stress factors in tumors.
Cancer Lett 218: 1–14
O’Dwyer PJ, Yao KS, Ford P, Godwin AK, Claytin M (1994) Effects of
hypoxia upon detoxicating enzyme activity and expression in HT29
colon adenocarcinoma cells. Cancer Res 54: 3082–3087
Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, Rana A,
Kumar V, Majumder PK, Avraham H, Davis RJ, Kharbanda S (1999)
Activation of p38 mitogen-activated protein kinase by PYK2/related
adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem 274:
10140–10144
Rice GC, Hoy C, Schimke RT (1986) Transient hypoxia enhances the
frequency of dihydrofolate reductase gene amplification in Chinese
hamster ovary cell. Proc Natl Acad Sci USA 83: 5978–5982
Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane
DP (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:
7555–7559
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM
(1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-
associated drug resistance. Br J Cancer 64: 809–814
Semenza GL (2003) Targeting HIF-1a for cancer therapy. Nat Rev Cancer 3:
721–732
Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y,
Matsuda H, Tsujimoto Y (1996) Induction of apoptosis as well as
necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2
and Bcl-XL. Cancer Res 56: 2161–2166
Stephan S, Datta K, Wang E, Li J, Brekken RA, Parangi S, Thorpe PE,
Mukhopadhyay D (2004) Effect of rapamycin alone and in combination
with antiangiogenesis therapy in an orthotopic model of human
pancreatic cancer. Clinical Cancer Res 10: 6993–7000
Tannock I, Guttman P (1981) Response of Chinese hamster ovary cells to
anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 42:
245–248
Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of
antineoplastic treatments by their differential toxicity toward putative
oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC
murine fibrosarcoma. Cancer Res 50: 3339–3344
Vasilevskaya I, O’Dwyer PJ (1999) Effects of geldanamycin on signaling
through AP-1 in hypoxic HT29 human colon adenocarcinoma cells.
Cancer Res 59: 3935–3940
Vaupel P, Kallinowski F, Okunief F (1989) Blood flow, oxygen and nutrient
supply, and metabolic microenvironment of humors: A review. Cancer
Res 49: 6449–6465
Wang AL, Tew KD (1985) Increased glutathione-S-transferase activity in
a cell line with acquired resistance to nitrogen mustards. Cancer Treat
Rep 69: 677–682
Yao KS, Clayton M, O’Dwyer PJ (1995) Apoptosis in human adenocarci-
noma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst 87:
117–122
Yao KS, O’Dwyer PJ (1995) Involvement of NF-e ˆB in the induction of
NAD(P)H: quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz
andmitomycin C. Biochem Pharmacol 49: 275–282
Yao KS, Xanthoudakis S, Curran T, O’Dwyer PJ (1994) Activation of AP-1
and of a nuclear redox factor ref-1 in the response of HT29 colon cancer
cells to hypoxia. Mol Cell Biol 14: 5997–6003
Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by
upregulating mdm2 KHT cells and increasing resistance to apoptosis.
Cancer Res 64: 4180–4189
Hypoxia conditioned cell lines and angiogenesis
K Yao et al
1363
British Journal of Cancer (2005) 93(12), 1356–1363 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s